News

The Pharma Letter14h
BRIEF—Nanoscope files first BLA for gene-agnostic retinal therapy
If approved, MCO-010 would be the first treatment to restore vision in legally blind RP patients without needing genetic ...
TMCnet15h
AAVantgarde Receives FDA Clearance to Progress Stargardt Disease Asset, AAVB-039, into CELESTE, a Phase 1/2 Clinical Trial
AAVantgarde is now initiating ‘CELESTE’, a first-in-human Phase 1/2 clinical trial in the United States, to evaluate the safety, tolerability, and initial efficacy of AAVB-039 in patients with ...